Navigation Links
Nottingham technology in heart development breakthrough
Date:2/25/2013

Technology developed at The University of Nottingham has been used in a breakthrough study aimed at developing the first comprehensive model of a fully functioning fetal heart.

The abdominal fetal ECG device, designed originally by academics in the University's Department of Electrical and Electronic Engineering and on commercial sale throughout the world since 2008 through the University spin-out company Monica Healthcare Ltd, has been used to observe living fetal hearts of babies in their mothers' wombs.

The collaborative study led by experts at The University of Leeds has discovered that the walls of the human heart are a disorganised jumble of tissue until relatively late in pregnancy with development much slower compared to other mammals.

Professor Barrie Hayes-Gill, Professor of Electronic Systems and Medical Devices at The University of Nottingham and joint founder and research director at Monica Healthcare said: "It's absolutely fantastic to see our device being used to detect fetal ECG morphology (i.e. ECG shape) in a non-invasive manner from the surface of the maternal abdomen. In this study the Monica device has been specifically deployed to observe the development of the fetal heart as it goes through gestation.

"It's an important development and we are delighted to see Nottingham technology playing such an integral part of the study. We expect that non-invasive morphological analysis during pregnancy and labour will become routine clinical practice in years to come as Monica continues to gain traction in the marketplace."

The fetal heart monitor is a portable, non-invasive device which attaches to the mother's abdomen and measures the electrical activity from the heart of the baby inside her womb. It is currently being used worldwide to monitor fetal heart rates during labour and delivery.

The device uses complex algorithms to correctly identify signals related to the fetal heart rate (FHR) usi
'/>"/>

Contact: Emma Thorne
emma.thorne@nottingham.ac.uk
44-115-951-5793
University of Nottingham
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Nottingham researchers lead worlds largest study into pre-eclampsia
2. Nottingham part of £20m investment for UK synthetic biology
3. Labor der Zukunft -- Tomorrows laboratory technology
4. The future of plant science - a technology perspective
5. The future of plant science a technology perspective
6. Ultracold matter technology from CU and SRI International licensed to Boulders ColdQuanta
7. UF researchers look for ways to make an emerging technology safe for environment
8. Breast cancer risk gene discovery fast tracked by new technology
9. Obese patients face higher radiation exposure from CT scans -- but new technology can help
10. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
11. Powerful sequencing technology decodes DNA folding pattern
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... let nerve cells send out electrical signals, Johns Hopkins ... that may offer a new way to protect crops ... way. , Their findingthat naturally occurring insect toxins ... a closely related onesuggests that insecticides can be designed ... bees. A summary of the research, led by Frank ...
(Date:7/10/2014)... BEDFORD, Mass. , June 30, 2014  Aware, ... of biometrics software and services, previously announced on June ... a special cash dividend of $1.75 per share, or ... record date of July 10, 2014 and a payment ... notified by NASDAQ that it had set an ex-dividend ...
(Date:7/10/2014)... According to the new market research report, ... (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile Devices, ... and Geography - Global Trends & Forecasts to 2014 ... Market is projected to cross $14.35 Billion by 2020, ... to 2020. Browse more than 78 market ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... Scientists have found that a large proportion of infants ... disease. The disease is the most prevalent acute wheezing ... admission to hospital in the first year of life in ... admitted to hospital for bronchiolitis - needing oxygen and help ...
... from small rings of naturally occurring plant DNA can ... embryonic plants where they are expressed, duplicated as plant ... -- a long-term goal for those interested in improving ... issue of PLoS-Genetics, a team of academic and commercial ...
... Research Hospital have identified the cell that gives rise to ... growth and development. The finding suggests for the first time ... induce fully developed neurons to multiply and coax the injured ... work appears in the Oct. 19 issue of the journal ...
Cached Biology News:Scientists find predisposition to bronchiolitis in some babies 2Transgenics transformed 2Transgenics transformed 3St. Jude identifies the specific cell that causes eye cancer, disproving long-held theory 2St. Jude identifies the specific cell that causes eye cancer, disproving long-held theory 3
(Date:7/10/2014)... 10, 2014 Senior supply chain management ... associations, addressed the challenges of “Reducing Cost, Lead Time, ... through strategic sourcing. Describing the partnership of the Bio ... Chain Management Institute ( SCMI) of the University ... 24 at the Kroc Institute of Peace and Justice ...
(Date:7/10/2014)... , July 10, 2014 Research and ... of the "International Photonic Integrated Circuit (Monolithic ... to 2019" report to their offering. ... The concept of photonic integration traces its roots ... The promise of photonic integration went unexplored and ...
(Date:7/10/2014)... journal PNAS (Proceedings of the National Academy of ... sleep deprivation have a significant effect on our metabolism. ... best time of day to test for diseases such ... effectively. , Researchers from the University of Surrey and ... between sleep deprivation, body clock disruption and metabolism, and ...
(Date:7/10/2014)... out for crude 3-D glasses, polarized glasses, and ... basic devices, used to trick the brain into ... rendered obsolete with the introduction of new holography ... TAU doctoral students Yuval Yifat, Michal Eitan, and ... on nanoantennas that could be used for security ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Time of day crucial to accurately test for diseases, new research finds 2Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... 22 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China ... develops, manufactures, and markets specialty pharmaceutical products in ... completed Phase I clinical trials of its novel ... to be the most widely prescribed class of ...
... SAN DIEGO, Sept. 22 Marshall Edwards, Inc. (Nasdaq: ... development of novel anti-cancer therapeutics, announced today that Daniel P. ... update on Marshall Edwards and its novel oncology programs at ... beginning at 4:30 p.m. EDT from the New York Palace ...
... Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to... -- HOERSHOLM, Denmark and SAN DIEGO, Sept. ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Biology Technology:China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 2China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 3China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 4Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 2Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 3Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 4Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 5Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 6Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 7Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 8Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 9Santaris Pharma A/S Advances miravirsen, the First microRNA-Targeted Drug to Enter Clinical Trials, Into Phase 2 to Treat Patients Infected With Hepatitis C Virus 10
Convenient 10X buffer concentrate used to maximize binding to the solid phase in microwell ELISA. Formulated to provide optimal pH and ionic strength for binding of antibodies and some antigens. Co...
A trigger solution for Flashlight labeled materials....
... The MiniOpticon 2-color real-time PCR detection system holds 48 ... array of 48 LEDs independently excites fluorescence (470-500 nm) ... detects emitted light (523-543 nm and 540-700 nm). This ... MJ Mini thermal cycler. System dimensions are 18 x ...
... novel procedure for the uniform amplification and ... DNA from small samples. This method has ... highly reproducible amplification and labeling procedure for ... Mini Kit module (QIAGEN) and a ULS ...
Biology Products: